Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection Clinical research trials and A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection. A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection clinical trial. Test subjects typically receive the most effective healthcare possible for their A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection

A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection



A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection

For Condition: HIV Infections
Status: Completed
Sponsor(s): Oxo Chemie GmbH ,
Synopsis: To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Dose Comparison, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Required: - Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with CD4 count <= 200 cells/mm3. Allowed: - PCP prophylaxis with aerosolized pentamidine in patients with CD4 count > 200 cells/mm3, only at the discretion of the treating physician. Patients must have: - HIV positivity. - Absolute CD4 count of 150 - 500 cells/mm3. - At least 6 months of prior zidovudine therapy. - No active opportunistic infection requiring ongoing therapy. - Life expectancy of at least 6 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Neoplasm other than basal cell carcinoma of the skin. - Clinically significant cardiac disease. - Abnormal neurological status by a standardized assessment including strength, reflex testing, and sensory testing. - Unwilling to comply with protocol requirements. Patients with the following prior conditions are excluded: History of myocardial infarction or arrhythmias. Prior Medication: Excluded within 2 weeks prior to study entry: - Antiretroviral agent or interferon. - Systemic biologic response modifiers, corticosteroids, cytotoxic chemotherapeutic agents, or other drugs that can cause neutropenia or significant nephrotoxicity. - Rifampin or rifampin derivatives. - Systemic anti-infectives. Required: - At least 6 months of prior zidovudine. Active drug or alcohol abuse.
Total Enrollment: 

Location and Contact Information:

Oncol Med Associates
Houston,  Texas,  77074
United States
 


Additional Information:
Study ID Numbers:  222A;  WF10-92-US-001
Study Start Date: 
Record last reviewed: March 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002119

Other Hiv Infections Studies:
1. T-20 in HIV Patients with Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs

2. The Healthy Life Choices Project in HIV-Positive Patients

3. A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex

4. Endothelial Dysfunction as a Risk Factor in HIV Study

5. Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma

Related Studies:

Other HIV Infections Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection
Modify your Search

  Other HIV Infections Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103